分组1 - Community Healthcare Trust (CHCT) reported quarterly funds from operations (FFO) of $0.55 per share, missing the Zacks Consensus Estimate of $0.57 per share, representing an FFO surprise of -2.66% [1] - The company posted revenues of $30.95 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 1.99%, compared to year-ago revenues of $29.3 million [2] - The current consensus FFO estimate for the coming quarter is $0.57 on $31.98 million in revenues, and for the current fiscal year, it is $2.31 on $129.28 million in revenues [7] 分组2 - Community Healthcare Trust shares have increased by approximately 7.4% since the beginning of the year, while the S&P 500 has declined by 0.1% [3] - The estimate revisions trend for Community Healthcare Trust was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] - The REIT and Equity Trust - Other industry is currently in the bottom 30% of the Zacks industries, which may impact stock performance [8]

Financial Results and Supplemental Information FISCAL FIRST QUARTER 2026 February 4, 2026 | Fiscal First Quarter 2026 Highlights 5 | | --- | | FINANCIALS | | Key Financial Data 7 | | Adjusted Net Income Attributable to The RMR Group Inc. Bridge 8 | | Distributable Earnings Bridge 9 | | AUM by Source 10 | | Management and Advisory Services Revenues by Source 12 | | Well-Covered Dividend 13 | | GAAP Results: Condensed Consolidated Statements of Income 14 | | GAAP Results: Earnings Per Common Share 16 | | GAAP ...

Group 1 - U.S. stock futures are lower, with Dow futures down approximately 100 points [1] - H.B. Fuller Company reported fourth-quarter earnings of $1.28 per share, exceeding the analyst consensus estimate of $1.23 per share [1] - H.B. Fuller reported quarterly sales of $894.788 million, which fell short of the analyst consensus estimate of $902.508 million [1] Group 2 - H.B. Fuller shares declined 3.7% to $62.32 in pre-market trading [2] - TryHard Holdings Ltd shares fell 11.8% to $28.20 in pre-market trading [3] - Caledonia Mining Corporation PLC shares tumbled 9.9% to $29.20 following the announcement of a $125 million offering of convertible senior notes [3] - Buckle Inc shares decreased 7.4% to $51.30 in pre-market trading [3] - NovaBay Pharmaceuticals Inc shares fell 5.6% to $12.02 in pre-market trading [3] - Trip.com Group Ltd shares dipped 4.1% to $60.20, following a 17% drop on Wednesday due to an investigation by China's SAMR for potential anti-monopoly violations [3] - Diversified Healthcare Trust shares fell 4% to $5.14 in pre-market trading [3] - Absci Corp shares declined 3.3% to $3.24 in pre-market trading [3] - Iperionx Ltd shares fell 3.3% to $47.99 in pre-market trading [3] - GeoPark Ltd shares decreased 2.7% to $7.55 in pre-market trading [3] - Esperion Therapeutics Inc shares fell 2% to $3.17 in pre-market trading [3]

Financial Performance - Net income attributable to The RMR Group Inc was $3414 thousand, or $020 per diluted share[18,22] - Adjusted Net Income Attributable to The RMR Group Inc was $3808 thousand, or $022 per diluted share[18,22] - Distributable Earnings was $14252 thousand, or $044 per diluted share[18,22] - Adjusted EBITDA was $20478 thousand with an Adjusted EBITDA Margin of 429%[18,22] - The company declared a quarterly dividend of $045 per share[11] Assets Under Management (AUM) - Total AUM reached $38968940 thousand, with $26703782 thousand (69%) from Managed Public Real Estate Capital and $12265158 thousand (31%) from Managed Private Real Estate Capital[18,32] Transactions and Liquidity - Two garden-style apartment communities were acquired for $147 million[9] - A $1 billion mortgage refinancing of Vertex Pharmaceuticals' headquarters in Boston was executed[9] - The company had $1623 million in total liquidity, including $623 million in cash on hand[19] Revenue Streams - Total Management & Advisory Services Revenues reached $45401 thousand[37,72] - Base Business Management & Advisory Revenues were $28760 thousand[37,71] - Base Property Management & Other Revenues amounted to $14574 thousand[37,71]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Diversified Healthcare (DHC) - DHC currently holds a Momentum Style Score of A, indicating strong momentum characteristics [3] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to the market [4] Price Performance - DHC shares have increased by 4.93% over the past week, outperforming the Zacks REIT and Equity Trust - Other industry, which rose by 1.26% [6] - Over the past month, DHC's price change is 9.76%, significantly higher than the industry's 1.38% [6] - In the last quarter, DHC shares have risen by 32.35%, and over the past year, they have gained 66.05%, while the S&P 500 has only increased by 7.27% and 15.21%, respectively [7] Trading Volume - DHC's average 20-day trading volume is 761,917 shares, which serves as a baseline for price-to-volume analysis [8] Earnings Outlook - In the past two months, one earnings estimate for DHC has increased, while none have decreased, raising the consensus estimate from $0.24 to $0.33 [10] - For the next fiscal year, one estimate has moved upwards with no downward revisions during the same period [10] Conclusion - Considering the strong price performance, positive earnings outlook, and high Momentum Style Score, DHC is positioned as a promising investment opportunity [12]

Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than traditional strategies of "buying low and selling high" [1] Group 1: Momentum Investing Strategy - Momentum investors often face challenges in determining the right entry point for fast-moving stocks, which can lead to investments with limited upside or potential downside [2] - A safer approach may involve investing in bargain stocks that have recently shown price momentum, utilizing tools like the Zacks Momentum Style Score to identify promising candidates [3] Group 2: Diversified Healthcare (DHC) Analysis - DHC has recently gained investor interest, reflected in a price increase of 0.1% over the past four weeks, positioning it as a strong candidate for momentum investing [4] - The stock has demonstrated significant performance, gaining 16.9% over the past 12 weeks, with a high beta of 2.61 indicating it moves 161% more than the market [5] - DHC holds a Momentum Score of A, suggesting it is an opportune time to invest in the stock for potential gains [6] Group 3: Earnings Estimates and Valuation - An upward trend in earnings estimate revisions has contributed to DHC's Zacks Rank 2 (Buy), indicating strong momentum among top-ranked stocks [7] - DHC is trading at a Price-to-Sales ratio of 0.67, suggesting it is undervalued, as investors pay only 67 cents for each dollar of sales [7] Group 4: Additional Investment Opportunities - Besides DHC, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting further investment opportunities [8] - Various Zacks Premium Screens are available to assist in identifying winning stock picks based on different investing styles [9]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $388.7 million, representing a 4% year-over-year increase [5] - Adjusted EBITDA RE was $62.9 million, and normalized FFO was $9.7 million or $0.04 per share [5] - Same property cash-based NOI was $62.6 million, a 70 basis point increase year-over-year, but a 9.5% decrease sequentially [14] Business Line Data and Key Metrics Changes - SHOP occupancy increased by 210 basis points year-over-year to 81.5%, marking the fourth consecutive quarter of occupancy growth [8] - SHOP revenues increased by 6.9% year-over-year, and consolidated SHOP NOI rose by 7.8% to $29.6 million [9] - Medical office and life science portfolio saw a consolidated occupancy increase of 370 basis points sequentially to 86.6% [10] Market Data and Key Metrics Changes - The company completed approximately 86,000 sq ft of leasing at weighted average rents 9% above prior rents for the same space [10] - Same property cash basis NOI for the medical office and life science portfolio increased by 1.6% year-over-year, with margins improving by 100 basis points to 58.9% [10] Company Strategy and Development Direction - The transition of AlerisLife Managed Communities is aimed at establishing a more efficient operating model aligned with industry trends [7] - New operating agreements include performance-based incentives and termination structures to enhance accountability [8] - The company is focused on reducing leverage through asset sales and improving performance in the SHOP segment [19] Management's Comments on Operating Environment and Future Outlook - Management expects to see a reduction in operator transition costs in Q4, estimating an impact of around $1.5-$2 million [22] - The company is maintaining its full-year SHOP NOI guidance range of $132-$142 million [20] - Management is optimistic about long-term performance improvements in the SHOP segment and overall portfolio [20] Other Important Information - The company has sold 44 properties for $396 million year-to-date and is under agreement to sell 38 additional properties for $237 million [12] - The company ended the quarter with approximately $351 million of liquidity, including $201 million of unrestricted cash [17] Q&A Session Summary Question: Impact of operator transition OpEx costs in Q4 - Management expects around $1.5-$2 million of impact in Q4, with continued increases in occupancy and some reductions in expenses [22] Question: Clarification on margin numbers - The 10.1% margin mentioned was a consolidated number [23] Question: Reason for the timing of the transition from AlerisLife - The transition was driven by AlerisLife's business needs and aims to bolster overall performance through new operators [25][26] Question: Expectations for SHOP occupancy by year-end - Management confirmed expectations for occupancy to be in the 82%-83% range by year-end [27] Question: Disposition activity and pipeline status - Approximately $200 million in dispositions is expected to close by year-end, with some transactions likely slipping into Q1 2026 [30]

Property and Occupancy - As of September 30, 2025, the company owned 335 properties across 34 states and Washington, D.C., with a total gross book value of real estate assets amounting to $6.66 billion[121][128]. - The SHOP segment reported an occupancy rate of 81.5%, up from 79.4% in the previous year, indicating a positive trend in occupancy[128]. - The Medical Office and Life Science Portfolio segment achieved an occupancy rate of 86.6%, compared to 80.8% in the prior year, reflecting strong demand[128]. - Occupancy rate for SHOP segment improved to 82.4% in Q3 2025 from 81.0% in Q3 2024[139]. - The number of properties in the senior living communities segment remained stable at 182 for both 2025 and 2024, with occupancy increasing to 81.6% from 80.6%[164]. - Occupancy rate for all properties improved to 86.6% in 2025 from 80.8% in 2024[169]. Financial Performance - Total revenues for Q3 2025 were $388.7 million, a 4.3% increase from $373.6 million in Q3 2024[136]. - Net loss for Q3 2025 was $164.0 million, compared to a net loss of $98.7 million in Q3 2024, representing a 66.2% increase in losses[138]. - Net operating income (NOI) for SHOP segment increased by 8.0% to $29.6 million in Q3 2025 from $27.4 million in Q3 2024[138]. - Medical Office and Life Science Portfolio reported a NOI decrease of 4.1%, from $27.8 million in Q3 2024 to $26.7 million in Q3 2025[138]. - Rental income for the Medical Office and Life Science Portfolio decreased by 8.9% to $48.2 million in Q3 2025 from $52.9 million in Q3 2024[144]. - The company reported a significant impairment of assets amounting to $93.2 million in Q3 2025, compared to $23.0 million in Q3 2024[138]. - The net loss for the nine months ended September 30, 2025, was $264,665 million, a decrease of 6.4% compared to a net loss of $282,809 million in 2024[163]. - Revenues for the nine months ended September 30, 2025, were $656,309, while expenses were $853,646, resulting in a loss from continuing operations of $363,993[234]. - The company reported a net loss of $355,570 for the nine months ended September 30, 2025[234]. Leasing and Rental Income - New leases in the Medical Office and Life Science Portfolio segment during Q3 2025 showed a weighted average rental rate increase of 29.8%[130]. - Total leasing costs and concession commitments for new leases in Q3 2025 amounted to $601,000, with a per square foot cost of $62.74[130]. - Annualized rental income from the Medical Office and Life Science Portfolio as of September 30, 2025, was $191.14 million[131]. - Average monthly rate for SHOP segment increased to $5,413 in Q3 2025, up from $5,142 in Q3 2024, reflecting a 5.3% increase[139]. - Total rental income for comparable properties decreased by $1,503, or 1.2%, to $119,518 for the nine months ended September 30, 2025, compared to $121,021 in 2024[170]. - Rental income for all properties decreased by $15,585, or 9.6%, to $146,020 for the nine months ended September 30, 2025, compared to $161,605 in 2024[169]. - Rental income for all other operations increased by $2,033, or 10.5%, to $21,346 for the nine months ended September 30, 2025, compared to $19,313 in 2024[173]. Expenses and Impairments - Property operating expenses for SHOP segment increased by 7.7% to $303.8 million in Q3 2025 from $284.6 million in Q3 2024[141]. - General and administrative expenses decreased to $32,966 million in 2025 from $27,763 million in 2024, a reduction of 18.7%[163]. - Impairment of assets increased significantly to $162,708 million in 2025 from $41,718 million in 2024, indicating a notable rise in asset impairment charges[163]. - Property operating expenses for comparable properties increased by $328, or 0.7%, to $47,834 in 2025, while non-comparable properties saw a decrease of $7,251, or 9.9%[171]. Cash Flow and Capital Expenditures - Cash and cash equivalents at the end of the nine months ended September 30, 2025, were $209,623, down from $261,400 in 2024, a decrease of 19.8%[199]. - Operating activities generated net cash of $492 for the nine months ended September 30, 2025, a significant decline from $94,028 in 2024[199]. - Total capital expenditures for the nine months ended September 30, 2025, were $108,645, down from $117,681 in 2024, a decrease of 7.5%[203]. - The company plans to invest approximately $20,405 in unspent leasing related obligations over the next 12 months[206]. - The company is currently redeveloping certain properties, primarily in managed senior living communities, which may require significant capital expenditures[207]. Debt and Financing - The company issued $375 million in aggregate principal amount of 7.25% senior secured notes due 2030, raising net proceeds of $364.726 million[223]. - The company has $334.370 million in outstanding senior secured notes due 2026, which are fully guaranteed by collateral properties[218]. - The company’s principal debt obligations at September 30, 2025, included $1.600 billion in senior unsecured notes and $709.370 million in senior secured notes[226]. - The company has a floating rate mortgage loan of $140,000 with an annual interest rate of 6.63%, resulting in an annual interest expense of $9,411[242]. - The company has fixed rate debt totaling $2,304,175 with an annual interest expense of $129,953 as of September 30, 2025[253]. - The company has no amounts outstanding under its revolving credit facility as of September 30, 2025[244]. Market Conditions and Economic Outlook - The company anticipates continued variability in labor, insurance, and food costs, which may impact cash flows during the management transition period[126]. - The company is closely monitoring economic uncertainties, including interest rates and inflation, which could affect financial conditions and market performance[126]. - The company expects future cash flows to depend on maintaining occupancy rates and controlling operating expenses amid inflationary pressures[198]. - A one percentage point increase in interest rates would raise the annual interest expense for the floating rate mortgage loan to $9,936, impacting earnings per share by $(0.04)[246]. - The company is exposed to market risks associated with interest rate fluctuations and employs derivative instruments to manage this risk[241]. Credit Ratings - Moody's upgraded the company's issuer credit rating from Caa3 to Caa1 in August 2025[224]. - S&P upgraded the company's issuer credit rating from CCC+ to B- in September 2025[225].

Financial Performance - Diversified Healthcare Trust reported a net loss of $164.0 million, or $0.68 per share, for Q3 2025, compared to a net loss of $91.6 million in Q2 2025[11]. - Normalized FFO for Q3 2025 was $9.7 million, or $0.04 per share, down 47.7% from $18.6 million in Q2 2025[12]. - Total revenues for Q3 2025 were $388,706,000, an increase of 4.0% compared to $373,640,000 in Q3 2024[21]. - Net loss for Q3 2025 was $(164,040,000), compared to a net loss of $(98,689,000) in Q3 2024, representing a 66.4% increase in losses year-over-year[21]. - Normalized FFO for Q3 2025 was $9,721,000, down from $18,572,000 in Q3 2024, indicating a decline of 47.7%[21]. - The company reported a net loss of $164,040 for Q3 2025, compared to a net loss of $98,689 for Q3 2024, reflecting a deterioration in financial performance[95]. - EBITDA for Q3 2025 was $(49,493), a significant decline from $29,861 in Q3 2024, highlighting operational challenges[95]. - DHC's total revenues for the nine months ended September 30, 2025, were $1.158 billion, compared to $1.115 billion for the same period in 2024, showing a growth of about 3.9%[93]. Occupancy and Revenue Metrics - The Senior Housing Operating Portfolio (SHOP) segment saw a year-over-year occupancy increase of 210 basis points to 81.5%, with average monthly rates growing by over 5%[5]. - The Medical Office and Life Science Portfolio achieved an occupancy rate of 86.6%, with weighted average rents 9% above prior rates[5]. - Average occupancy rate for Senior Living properties improved to 81.5% in Q3 2025, up from 79.4% in Q3 2024, representing a 210 basis point increase[68]. - Medical Office and Life Science portfolio occupancy increased to 86.6% in Q3 2025, up from 80.8% in Q3 2024[69]. - The total gross book value of the Medical Office and Life Science Portfolio is $1.718 billion, representing 25.8% of total real estate assets[55]. - The SHOP segment represents 69.1% of the gross book value of real estate assets, with total revenues of $333.39 million, accounting for 85.8% of total revenues[55]. Asset and Debt Management - DHC's cash and cash equivalents totaled approximately $209.6 million as of September 30, 2025[11]. - DHC entered into a $1.0 billion mortgage loan secured by Vertex Pharmaceuticals' headquarters, resulting in a $28.0 million distribution[11]. - The company plans to repay its 2026 debt maturity as early as year-end 2025, with no debt maturities until 2028[6]. - Total assets as of September 30, 2025, were $4,683,974,000, a decrease from $5,137,005,000 as of December 31, 2024[17]. - Total liabilities increased to $2,995,244,000 as of September 30, 2025, compared to $3,178,162,000 at the end of 2024[17]. - Total equity decreased to $1,688,730,000 as of September 30, 2025, down from $1,958,843,000 at the end of 2024, reflecting a decline of 13.8%[17]. - The leverage ratio of net debt to total gross assets is 38.1% as of September 30, 2025, an increase from 37.3% in the previous quarter[30]. - The company has a total debt to adjusted total assets ratio of 40.7%, remaining below the allowable maximum of 60.0%[31]. Capital Expenditures and Investments - For the three months ended September 30, 2025, total recurring capital expenditures amounted to $40,562, compared to $29,329 for the previous quarter[35]. - Capital expenditures for the Medical Office and Life Science Portfolio for the nine months ended September 30, 2025, totaled $17,848[35]. - The company has disposed of 44 properties since January 1, 2025, generating a total gross sales price of $395.805 million[40]. - The company has a total unsecured fixed rate debt of $1,600,000, with a weighted average interest rate of 5.059%[23]. Operational Efficiency and Management - The transition of 116 AlerisLife-managed communities to new operators is on track, with approximately 73% completed as of November 3, 2025[6]. - The company is focused on redevelopment and repositioning activities, which are expected to enhance property values and operational efficiency[134]. - DHC's management believes that being managed by RMR provides a competitive advantage due to RMR's extensive experience in the real estate industry[87]. - The company is actively managing its financial covenants to ensure compliance and maintain access to capital[119]. Leasing and Tenant Information - The total annualized rental income from tenants as of September 30, 2025, is $219.2 million, with Advocate Aurora Health contributing 7.7% of this income[79]. - The company executed a total of 89 leases in the third quarter of 2025, comprising 10 new leases and 76 renewals[1]. - The cumulative percentage of total annualized rental income expiring by 2028 is projected to be 40.9%[80]. - The company has a diverse tenant base, with 50.6% of annualized rental income coming from tenants not listed individually[79].

Core Insights - The article discusses the importance of enabling Javascript and cookies in browsers to ensure proper functionality and access to content [1] Group 1 - The article emphasizes that users may be blocked from proceeding if an ad-blocker is enabled [1]